Evidence map›Paper›PMID 42919430›Full record

ArticleActa neuropathologica communications2026

Cytotoxic activity of selinexor in BRAF

Constantia Zeiser, Marta Emperador, Sonja Herter, Lisa Sigaud, Alexandra Stroh-Dege, Anna Loboda, Anna Kolodziejczak, Simon Zeuner, Lea Joy Digel, Karen Frese and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Constantia ZeiserHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Marta EmperadorHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Sonja HerterHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Lisa SigaudHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Alexandra Stroh-DegeHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Anna LobodaHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Anna KolodziejczakHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Simon ZeunerHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Lea Joy DigelHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Karen FreseDepartment of Medicine III, Heidelberg University, German Centre for Cardiovascular Research (DZHK), partner site Heidelberg/Mannheim, 69120, Heidelberg, Germany.
Bruno ChilianTRI Thinking Research Instruments GmbH, Große Freiheit 77, 22767, Hamburg, Germany.
Micaela FreitasPrecomb Therapeutics AG, Hombrechtikon, Switzerland.
Jens M KelmPrecomb Therapeutics AG, Hombrechtikon, Switzerland.
Ingrid ǾraLund University, Lund, Sweden.
Daniel VoglDepartment of Neurosurgery, Section of Pediatric Neurosurgery, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, Baden-Württemberg, 72076, Tuebingen, Germany.
Martin Ulrich SchuhmannDepartment of Neurosurgery, Centre of Neurofibromatosis and Schwannomatosis, Centre for Rare Diseases, Division of Pediatric Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
Heike PeterzielHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Romain SigaudHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Florian SeltHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Till MildeHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
Ina OehmeHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany. i.oehme@kitz-heidelberg.de.ORCID https://orcid.org/0000-0002-0827-2356

Funding

DKTK JF Upgrade Next Gen LOGGIC B310-JF-LOGGIC-MDE
6 · The paper itself

Abstract

Pediatric low-grade gliomas (pLGGs) are the most common primary brain tumors in children and frequently harbor activating RAS/MAPK pathway alterations, including BRAF

Indexed as

Antineoplastic AgentsBrain NeoplasmsGliomaHydrazinesProto-Oncogene Proteins B-rafTriazolesAnimalsCell Line, TumorChildExportin 1 ProteinHumansKaryopherinsMutationReceptors, Cytoplasmic and NuclearAntineoplastic AgentsBRAF protein, humanExportin 1 ProteinHydrazinesKaryopherinsProto-Oncogene Proteins B-rafReceptors, Cytoplasmic and NuclearselinexorTriazoles3D cultureBrain tumorDrug repurposingExportin-1 (XPO1)Ex vivo drug profilingFunctional precision oncologyMAPK pathwayPediatric low-grade gliomaSynergy screeningTargeted therapy

Identifiers

PMID42919430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.